BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ:OCUL), today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities

AVEO Oncology announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock.

Experienced Industry Leader Elevates Research and Development Capabilities, Joins Company At An Important Development Juncture

Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that it has entered into an at-the-market equity offering sales agreement with Canaccord Genuity LLC.

Active Motif, a company with the vision of bringing the field of epigenetics into personalized medicine, announces access to a pre-print publication associated with their COVID-19 efforts in China to isolate, develop, and deliver high-value fully human recombinant SARS-CoV-2 antibodies to the market.

Abivax SA (Euronext Paris:FR0012333284 - ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that it has received € 5m in non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE - Prêts Garantis par l’Etat).

Novus Acquisition and Development, Corp. (OTC PINK:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is the nation’s first health carrier offering cannabis health plans to recreational and medicinal users, is pleased to announce the hiring of Mark Kuban to the Novus Cannabis MedPlan team.

AIM ImmunoTech (NYSE American:AIM), today provided an update on the commercial launch of Ampligen® for the treatment of severe Chronic Fatigue Syndrome (CFS) in Argentina.

Hemogenyx Pharmaceutical plc is pleased to announce progress in relation to its COVID-19 program.

Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates